100 related articles for article (PubMed ID: 19270500)
1. Beyond apoptosis of JNK1 in liver cancer.
Chen F; Castranova V
Cell Cycle; 2009 Apr; 8(8):1145-7. PubMed ID: 19270500
[TBL] [Abstract][Full Text] [Related]
2. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
Yan F; Wang XM; Liu ZC; Pan C; Yuan SB; Ma QM
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):287-95. PubMed ID: 20525557
[TBL] [Abstract][Full Text] [Related]
3. JNK1, a potential therapeutic target for hepatocellular carcinoma.
Chen F; Beezhold K; Castranova V
Biochim Biophys Acta; 2009 Dec; 1796(2):242-51. PubMed ID: 19591900
[TBL] [Abstract][Full Text] [Related]
4. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma.
Chang Q; Chen J; Beezhold KJ; Castranova V; Shi X; Chen F
Mol Cancer; 2009 Aug; 8():64. PubMed ID: 19686584
[TBL] [Abstract][Full Text] [Related]
5. JNK1/2 and ERK1/2 provides vital clues about tumor recurrence and survival in hepatocellular carcinoma patients.
Gao X; Shan W; Liu X; Zhang J; Zheng J; Yao H
Future Oncol; 2018 Oct; 14(24):2471-2481. PubMed ID: 29714074
[TBL] [Abstract][Full Text] [Related]
6. Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.
Zhe Y; Li Y; Liu D; Su DM; Liu JG; Li HY
Tumour Biol; 2016 Oct; 37(10):13951-13959. PubMed ID: 27492456
[TBL] [Abstract][Full Text] [Related]
7. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.
Liu J; Minemoto Y; Lin A
Mol Cell Biol; 2004 Dec; 24(24):10844-56. PubMed ID: 15572687
[TBL] [Abstract][Full Text] [Related]
8. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells.
Hsieh YH; Wu TT; Huang CY; Hsieh YS; Hwang JM; Liu JY
Cancer Res; 2007 May; 67(9):4320-7. PubMed ID: 17483345
[TBL] [Abstract][Full Text] [Related]
9. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.
Sakurai T; Maeda S; Chang L; Karin M
Proc Natl Acad Sci U S A; 2006 Jul; 103(28):10544-51. PubMed ID: 16807293
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest.
Kuntzen C; Sonuc N; De Toni EN; Opelz C; Mucha SR; Gerbes AL; Eichhorst ST
Cancer Res; 2005 Aug; 65(15):6780-8. PubMed ID: 16061660
[TBL] [Abstract][Full Text] [Related]
11. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer.
Chang Q; Zhang Y; Beezhold KJ; Bhatia D; Zhao H; Chen J; Castranova V; Shi X; Chen F
J Hepatol; 2009 Feb; 50(2):323-33. PubMed ID: 19041150
[TBL] [Abstract][Full Text] [Related]
12. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells.
Li Q; Liu G; Shao D; Wang J; Yuan H; Chen T; Zhai R; Ni W; Tai G
Int J Biochem Cell Biol; 2015 Feb; 59():116-25. PubMed ID: 25526895
[TBL] [Abstract][Full Text] [Related]
13. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of JNK1 expression decreases migration and invasion of mouse hepatocellular carcinoma cell line in vitro.
Zhang YH; Wang SQ; Sun CR; Wang M; Wang B; Tang JW
Med Oncol; 2011 Dec; 28(4):966-72. PubMed ID: 20490718
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells.
Eguchi R; Fujimori Y; Takeda H; Tabata C; Ohta T; Kuribayashi K; Fukuoka K; Nakano T
J Cell Physiol; 2011 Mar; 226(3):762-8. PubMed ID: 20799280
[TBL] [Abstract][Full Text] [Related]
16. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
[TBL] [Abstract][Full Text] [Related]
17. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis.
Kodama Y; Taura K; Miura K; Schnabl B; Osawa Y; Brenner DA
Gastroenterology; 2009 Apr; 136(4):1423-34. PubMed ID: 19249395
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
Gancz D; Donin N; Fishelson Z
Mol Immunol; 2009 Dec; 47(2-3):310-7. PubMed ID: 19864026
[TBL] [Abstract][Full Text] [Related]
19. Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt.
Biswas KK; Tancharoen S; Sarker KP; Kawahara K; Hashiguchi T; Maruyama I
FEBS Lett; 2006 Jan; 580(2):703-10. PubMed ID: 16412424
[TBL] [Abstract][Full Text] [Related]
20. MECP2 promotes cell proliferation by activating ERK1/2 and inhibiting p38 activity in human hepatocellular carcinoma HEPG2 cells.
Zhao LY; Zhang J; Guo B; Yang J; Han J; Zhao XG; Wang XF; Liu LY; Li ZF; Song TS; Huang C
Cell Mol Biol (Noisy-le-grand); 2013 Nov; Suppl 59():OL1876-81. PubMed ID: 24199952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
